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Background
Pritelivir, an inhibitor of the viral helicase–primase complex, exhibits antiviral 
 activity in vitro and in animal models of herpes simplex virus (HSV) infection. We 
tested the efficacy and safety of pritelivir in otherwise healthy persons with genital 
HSV-2 infection.
Methods
We randomly assigned 156 HSV-2–positive persons with a history of genital herpes 
to receive one of four doses of oral pritelivir (5, 25, or 75 mg daily, or 400 mg weekly) 
or placebo for 28 days. Participants obtained daily swabs from the genital area for 
HSV-2 testing, which was performed with a polymerase-chain-reaction assay. Partici-
pants also maintained a diary of genital signs and symptoms. The primary end point 
was the rate of genital HSV shedding.
Results
HSV shedding among placebo recipients was detected on 16.6% of days; shedding 
among pritelivir recipients was detected on 18.2% of days among those receiving 
5 mg daily, 9.3% of days among those receiving 25 mg daily, 2.1% of days among 
those receiving 75 mg daily, and 5.3% of days among those receiving 400 mg 
weekly. The relative risk of viral shedding with pritelivir, as compared with placebo, 
was 1.11 (95% confidence interval [CI], 0.65 to 1.87) with the 5-mg daily dose, 
0.57 (95% CI, 0.31 to 1.03) with the 25-mg daily dose, 0.13 (95% CI, 0.04 to 0.38) 
with the 75-mg daily dose, and 0.32 (95% CI, 0.17 to 0.59) with the 400-mg weekly 
dose. The percentage of days with genital lesions was also significantly reduced, 
from 9.0% in the placebo group to 1.2% in both the group receiving 75 mg of 
pritelivir daily (relative risk, 0.13; 95% CI, 0.02 to 0.70) and the group receiving 
400 mg weekly (relative risk, 0.13; 95% CI, 0.03 to 0.52). The rate of adverse events 
was similar in all groups.
Conclusions
Pritelivir reduced the rates of genital HSV shedding and days with lesions in a dose-
dependent manner in otherwise healthy men and women with genital herpes. 
(Funded by AiCuris; ClinicalTrials.gov number, NCT01047540.)
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T reatment of genital infections with the herpes simplex virus (HSV) relies on nucleoside analogues that inhibit the 
HSV DNA polymerase after phosphorylation by 
the viral thymidine kinase.1 These compounds, 
which were developed three decades ago and are 
in widespread use today, ameliorate clinical dis-
ease. However, they do not abrogate viral shedding 
and only partially reduce the risk of transmission 
to sexual partners.2-4 In immunocompromised 
persons, resistance to nucleoside analogues de-
velops occasionally, and treatment options for 
acyclovir-resistant HSV are limited.5,6
The thiazolylamide pritelivir (BAY 57-1293; 
AIC316) is the first in a new class of antiviral 
agents that inhibit HSV replication by targeting 
the viral helicase–primase enzyme complex. 
Pritelivir binds to the complex composed of the 
gene products of UL5, UL8 and UL52.7 Unlike 
the nucleoside analogues, pritelivir does not re-
quire activation by phosphorylation, and it is 
active in uninfected cells. Pritelivir exhibits po-
tent in vitro activity against HSV-1 and HSV-2 
isolates, including strains resistant to nucleoside 
analogues, and has shown efficacy in studies in 
animals, including a study of genital infection in 
guinea pigs.8-10 In phase 1 studies of pritelivir, 
no safety concerns were identified, and the ter-
minal half-life reported was up to 80 hours.11
To investigate the efficacy and safety of pri-
telivir in the treatment of genital infection with 
HSV-2 and to determine the most effective, safe 
dose, we conducted a proof-of-concept study to 
evaluate the effect of four different doses of oral 
pritelivir on mucocutaneous viral shedding in 
adults with genital HSV-2 infection.
Me thods
Study Participants
We enrolled otherwise healthy adults (≥18 years 
of age) who were seropositive for HSV-2 and had 
a history of genital herpes. Eligible participants 
had a history of one to nine recurrences of geni-
tal herpes per year. Other inclusion criteria were 
a body-mass index (the weight in kilograms di-
vided by the square of the height in meters) be-
tween 18 and 35, the use of effective contracep-
tion, and normal results on laboratory tests, 
including electrocardiography and urinalysis. 
Infection with the human immunodeficiency vi-
rus or with hepatitis B or C virus, pregnancy, 
immunosuppression, treatment with medica-
tions that induce drug-metabolizing enzymes or 
transporters (e.g., carbamazepine or phenytoin) 
were exclusion criteria. Receipt of other anti-HSV 
therapy, consumption of grapefruit, and intake 
of quinine or products containing quinidine were 
not permitted during the study. All participants 
provided written informed consent.
Study Design and Oversight
The study was designed as a randomized, paral-
lel, double-blind, placebo-controlled study by in-
vestigators at the University of Washington and 
by the sponsor, AiCuris, and was managed by 
FHI 360. The statistical analyses were performed 
by authors at the University of Washington, ac-
cording to a statistical plan previously developed 
by the academic and industry investigators. Both 
the academic and industry authors contributed to 
all drafts of the manuscript and approved the 
submission of the final manuscript for publica-
tion. All authors had full access to all data, veri-
fied the accuracy of the data, and vouch for the 
fidelity of the study to the protocol and for the 
completeness of the data presented. The study 
was approved by the institutional review board at 
each study center. For full details of the design 
and conduct of the study, see the protocol, avail-
able with the full text of this article at NEJM.org.
Study Drug
The four dosing regimens for pritelivir were a 
loading dose of 20 mg followed by a daily dose of 
5 mg, a loading dose of 100 mg followed by a 
daily dose of 25 mg, a loading dose of 300 mg 
followed by a daily dose of 75 mg, and a weekly 
dose of 400 mg. The regimen for the administra-
tion of placebo was the same as it was for the 
administration of pritelivir. The study drug was 
taken for a period of 28 days.
Study Procedures
Eligible participants were randomly assigned to 
one of the five study groups in a 1:1:1:1:1 ratio. 
A statistician who was not involved in the con-
duct of the study generated the randomization 
schema using the permuted-blocks method, with 
stratification according to sex and study site.
Throughout the study period, participants 
obtained daily swabs of genital skin and mucosa 
and delivered them to the study site weekly for 
the purpose of HSV detection.3,4,12 Participants 
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also maintained a diary of genital signs and symp-
toms. If a lesion developed that was consistent 
with genital herpes, an additional swab was ob-
tained from the lesion. Participants who had a re-
currence (i.e., papules, vesicles or pustules, ulcers, 
or crusts) during the study were asked to return 
to the clinic for an examination within 24 hours.
Laboratory Studies
Western blot analysis was used to confirm HSV-2 
serostatus.13 Samples of genital secretions were 
analyzed for HSV DNA with a real-time, quantita-
tive, fluorescent polymerase-chain-reaction (PCR) 
assay (TaqMan) at the University of Washington 
Virology Laboratory.14 Test results were consid-
ered to be positive when 150 HSV DNA copies per 
milliliter or more were detected.15
Samples with an HSV DNA copy number of 
more than 5000 per milliliter were sequenced 
to detect mutations in UL5 and UL52. Primers 
(Table S2 in the Supplementary Appendix, avail-
able at NEJM.org) flanking the regions known 
to mediate resistance to helicase–primase in-
hibitors16 and Platinum TaqDNA Polymerase 
High Fidelity reagents (Invitrogen) were used 
to generate PCR products. The PCR products 
were sequenced according to inner primers 
with the use of BigDye Terminator (version 3.1) 
cycle- sequencing technology.17,18 Sequencing data 
were analyzed with the Sequencher 4.10 pro-
gram (HSV-2 reference strain, HG52; NCBI ac-
cession number, NC_001798.1)19 and were up-
loaded to GenBank under accession numbers 
KF008267-KF008349 and KF008350-KF008432.
Safety Evaluation
Safety was evaluated by examining the rate, nature, 
duration, and severity of adverse events in each 
study group; events were graded with the use of the 
Division of Acquired Immunodeficiency Syndrome 
(DAIDS) table of adverse events (http://rsc.tech-res 
.com/Document/safetyandpharmacovigilance/Table 
_for_Grading_Severity_of_Adult_Pediatric_Adverse 
_Events.pdf). Additional safety assessments in-
cluded physical examination, laboratory measure-
ments, and electrocardiography.
Statistical Analysis
The frequency of HSV-2 detection (the shedding 
rate) was defined as the number of days with a 
genital swab that was positive for HSV divided by 
the total number of days on which genital swabs 
were obtained. The primary end point was the 
reduction in the HSV shedding rate among par-
ticipants receiving pritelivir relative to the shed-
ding rate among participants receiving placebo. 
Secondary end points included the rate of genital 
lesions, the reduction of HSV DNA copies, the 
frequency of herpes recurrence, and the rate of 
subclinical shedding.
The intention-to-treat analysis included all pa-
tients who took at least one dose of study medica-
tion and obtained at least one swab of genital 
secretions. Poisson regression with overdisper-
sion was used to estimate the effect of treatment 
on the rates of viral shedding and lesion recur-
rence, with terms included for treatment and sex 
and a random term for investigational site. On 
days when HSV was detected, the log10 number of 
HSV DNA copies was compared between each of 
the pritelivir groups and the placebo group with 
the use of generalized estimating equations that 
accounted for the correlation between repeated 
measures per participant. The concordance be-
tween the detection of HSV from swabs obtained 
by a participant and detection from those ob-
tained by an investigator was assessed with the 
kappa statistic and the Spearman coefficient.
R esult s
Study Population
The trial was conducted between April and De-
cember 2010 at seven sites in the United States. 
Among 261 persons screened, 156 underwent 
randomization; 1 person who underwent ran-
domization was deemed ineligible and did not 
receive the study drug or participate in the study. 
The predominant reason for ineligibility was an 
absence of serologically confirmed HSV-2 infec-
tion. The median age of the participants was 
41 years; 104 (67%) were women, and most were 
white (Table 1). The median duration of genital 
herpes before study entry was 11 years; 21% of 
the participants were receiving suppressive ther-
apy before study entry. A total of 147 participants 
(94%) completed the study. Participants discon-
tinued treatment prematurely for the following 
reasons: withdrawal of consent (4 participants), 
adverse events (3 participants), loss to follow-up 
(2 participants), pregnancy (1 participant), and 
noncompliance with the protocol (1 participant). 
The median percentage of days on which swabs 
were obtained was 100% (range, 11 to 100%); 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV OF UTAH ECCLES on March 18, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 370;3 nejm.org january 16, 2014204
80% of the participants obtained more than 96% 
of the swabs. Mean adherence to the study medi-
cation, as calculated according to the pill count, 
was 99% (median, 100%; range, 72 to 100) with 
94% of participants taking more than 95% of the 
study drug; adherence was similar in all study 
groups. There was a high concordance in the fre-
quency with which HSV was detected and the 
quantity of HSV DNA detected in the swabs ob-
tained by participants and the swabs obtained by 
the investigators (r = 0.87, P<0.001) (Fig. S1 in the 
Supplementary Appendix).
Effect of Pritelivir on Viral Shedding
A total of 4180 daily genital swabs were obtained, 
435 of which (10.4%) were positive for HSV. Gen-
ital HSV was detected at least once in 87 of the 
155 participants (56%). The rate of HSV shedding 
in the placebo group was 16.6%; among the 
groups receiving pritelivir daily, the rate was 18.2% 
with 5 mg, 9.3% with 25 mg, and 2.1% with 75 mg; 
in the group receiving 400 mg weekly, the rate 
was 5.3% (Table 2 and Fig. 1A). The relative risk 
of viral shedding with pritelivir as compared 
with placebo was 1.11 (95% confidence interval 
[CI], 0.65 to 1.87; P = 0.70) at a daily dose of 5 mg, 
0.57 (95% CI, 0.31 to 1.03; P = 0.06) at a daily 
dose of 25 mg, 0.13 (95% CI, 0.04 to 0.38; 
P<0.001) at a daily dose of 75 mg, and 0.32 
(95% CI, 0.17 to 0.59; P<0.001) at a weekly dose 
of 400 mg (Table 2).
When HSV was detected, the median log10 
number of HSV DNA copies was 5.1 with placebo, 
4.5 with 5 mg of pritelivir daily, 3.6 with 25 mg 
daily, 2.4 with 75 mg daily, and 3.6 with 400 mg 
weekly (P<0.001 for the comparisons of placebo 
with doses of pritelivir of 25 mg or more) 
(Fig. 1B). Thus, as compared with placebo, pri-
telivir significantly reduced both the frequency 
of HSV shedding on the genital mucosa and the 
quantity of the virus detected when break-
through shedding occurred. A similar dose re-
sponse was observed for subclinical viral shed-
ding. The overall rate of subclinical shedding 
Table 1. Demographic and Clinical Characteristics of the Study Participants.*
Characteristic
Placebo
(N = 30) Pritelivir
5 mg  
Daily
(N = 33)
25 mg  
Daily
(N = 32)







Median 42 36 36 43 44
Range 24–64 19–71 22–63 20–67 19–67
Female sex — no. (%) 21 (70) 22 (67) 21 (66) 20 (69) 20 (65)
White race — no. (%) 21 (70) 25 (76) 27 (84) 20 (69) 23 (74)
Seropositivity for HSV-1 and HSV-2 — no. (%) 14 (47) 20 (61) 14 (44) 10 (34) 16 (52)
Duration of genital herpes — yr
Median 15 10 10 15 9
Range 1–35 1–31 1–52 1–40 1–30
Recurrences of genital herpes before study 
entry — no./yr†‡
Median 4 3 3 4 4
Range 1–9 1–9 1–9 1–9 1–9
Treatment with suppressive agent before 
study entry — no. (%)
7 (23) 7 (21) 7 (22) 7 (24) 4 (13)
Total no. of days swabs obtained by 
participants and investigators
833 846 883 766 852
* HSV-1 denotes herpes simplex virus type 1, and HSV-2 type 2.
† Data for this variable were not available at one of the study sites, where there were 18 participants.
‡ For patients receiving suppressive therapy, the number of recurrences is the number in the period before the initiation 
of that therapy.
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was 9.8% with placebo, 11.9% with 5 mg of 
pritelivir daily, 7.4% with 25 mg daily, 1.6% with 
75 mg daily, and 4.8% with 400 mg weekly 
(Fig. 1C). The relative risks of subclinical shed-
ding at pritelivir doses of 5 mg daily, 25 mg 
daily, 75 mg daily, and 400 mg weekly were 1.26 
(95% CI, 0.67 to 2.35; P = 0.48), 0.73 (95% CI, 
0.37 to 1.47; P = 0.38) , 0.16 (95% CI, 0.05 to 0.49; 
P = 0.001), and 0.47 (95% CI, 0.24 to 0.91; 
P = 0.02), respectively.
Pritelivir reduced viral shedding in both men 
and women. For example, among men in the 
75-mg group, HSV shedding occurred on 3.2% 
of days as compared with 12.5% of days among 
men in the placebo group; among women in the 
75-mg group, HSV shedding occurred on 1.6% 
of days as compared with 18.3% of days in the 
placebo group. No significant interaction was 
detected between treatment with 75 mg of pri-
telivir daily and sex, nor was there a significant 
interaction between treatment and site.
Effect of Pritelivir on Genital Lesions
To assess the effect of pritelivir on the clinical 
manifestations of genital infection with HSV-2, 
we calculated the percentage of days on which 
participants had genital lesions according to 
study group. Genital lesions were noted on 9.0% 
of days with placebo, 12.5% with 5 mg of priteli-
vir, 3.5% with 25 mg, 1.2% with 75 mg, and 1.2% 
with 400 mg (Fig. 1D). The risk of genital lesions 
with pritelivir as compared with placebo was 
1.39 (95% CI, 0.59 to 3.30; P = 0.46) with 5 mg of 
pritelivir daily, 0.41 (95% CI, 0.16 to 1.09; P = 0.07) 
with 25 mg daily, 0.13 (95% CI, 0.02 to 0.70; 
P = 0.02) with 75 mg daily, and 0.13 (95% CI, 0.03 
to 0.52; P = 0.004) with 400 mg weekly. In addi-
tion, we observed 12 recurrences in participants 
receiving placebo, 18 in participants receiving 
5 mg of pritelivir daily, 12 in those receiving 
25 mg daily, 3 in those receiving 75 mg daily, 
and 6 in those receiving 400 mg weekly (P = 0.04 
for the comparison of placebo with 75 mg of 
pritelivir daily).
Viral shedding at the time of lesion recur-
rence was also reduced in a dose-related manner 
among participants receiving pritelivir (Table 2). 
In the placebo group, HSV was detected on 
85.3% of days on which participants had lesions, 
as compared with 60.4% of days in the group re-
ceiving 5 mg of pritelivir daily, 50.0% in the group 
receiving 25 mg daily, 44.4% in the group receiv-
ing 75 mg daily, and 50.0% in the group receiving 
400 mg weekly. The median HSV DNA log10 
copy number was 6.1 among participants with 
lesions who were receiving placebo. The log10 
copy number was decreased somewhat among 
participants receiving lower doses of pritelivir, 
reaching 2.9 at a dose of 75 mg daily (P<0.001 
for the comparison of 75 mg of pritelivir daily 
with placebo) (Table 2).
Viral Resistance
Analysis of the resistance-associated regions of UL5 
and UL52 revealed variations in DNA in all study 
groups as compared with the HSV-2 reference se-
quence. Four changes in UL5 were identified in 
five participants. Among these four changes, three 
were synonymous (G879A [in a recipient of 5 mg 
of pritelivir daily], C996T [in a placebo recipient], 
and G1053A [in a recipient of 400 mg of pritelivir 
weekly]) and one was nonsynonymous (A1001G 
[in a recipient of 5 mg of pritelivir daily]); the 
corresponding amino acid change is H334R, 
which is not within or downstream of the fourth 
functional motif of UL5 and is therefore not con-
sidered to confer resistance to pritelivir.16 In 
UL52, two synonymous changes were identified 
in two participants (G2649A [in a placebo recipi-
ent] and C2676T [in a recipient of 25 mg of pri-
telivir daily]). All sequences within participants 
were identical.
Adverse Events
No pattern of adverse events or laboratory abnor-
malities emerged during the study (Table 3, and 
Table S1 in the Supplementary Appendix). One 
serious adverse event occurred in a participant 
receiving 25 mg of pritelivir daily, who was hospi-
talized for pancreatitis 2 weeks after completing 
treatment; a review of the participant’s medical 
history revealed prior alcohol-related pancreatitis 
and probable continued alcohol intake. The num-
ber of days with nausea was highest in the group 
receiving 400 mg of pritelivir per week (33 days 
of nausea) and the group receiving 5 mg per day 
(44 days), although a single participant accounted 
for 75% of the days of nausea in the group receiv-
ing 400 mg per week. Three participants receiving 
pritelivir discontinued treatment because of ad-
verse events: one participant receiving 5 mg daily 
discontinued treatment because of moderate 
headache, nausea, chest pain, and dyspnea; one 
receiving 25 mg daily discontinued treatment be-
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cause of suspected systemic lupus erythematosus; 
and one receiving 400 mg per week discontinued 
treatment because of mild anxiety.
Discussion
Our study showed that pritelivir, an HSV-specific 
helicase–primase inhibitor, significantly reduces 
the frequency of genital HSV shedding and lesions 
in otherwise healthy men and women with geni-
tal HSV-2 infection. The effect was dose-related, 
with a daily dose of 75 mg having the greatest 
antiviral effect. Furthermore, at this dose, priteli-
vir reduced the quantity of HSV in breakthrough 
shedding by more than 98%. Although our study 
was not powered to evaluate the effect of priteli-
vir on recurrences of symptomatic genital her-
pes, we did observe significant reductions in the 
number of days of genital lesions at doses of 
75 mg daily and 400 mg weekly that paralleled 
the trend toward fewer recurrences at these doses.
In our small study, pritelivir, when adminis-
tered daily for 4 weeks, was not associated with 
any clinical, laboratory, or cardiac abnormalities 
that emerged during treatment. Reports of nau-
sea did not appear to be related to the dose of 
pritelivir. (Nausea was not observed in phase 1 
studies at higher doses.11) Sequencing of sam-
ples obtained before and after treatment sug-
gests that drug resistance did not emerge, even 







Relative Risk  
or Change in  
Copy Number  





Rate of genital HSV shedding — no. of days/total no. (%) 138/833 (16.6) 154/846 (18.2) 1.11  
(0.65 to 1.87)
0.70 82/883 (9.3)
Rate of subclinical shedding — no. of days/total no. (%) 74/758 (9.8) 88/737 (11.9) 1.26 
(0.67 to 2.35)
0.48 61/825 (7.4)
Rate of lesional shedding — no. of days/total no. (%) 64/75 (85.3) 64/106 (60.4) 0.85  
(0.59 to 1.24)
0.39 15/30 (50.0)
HSV DNA — log10 copy no.
Overall
Median 5.1 4.5 −0.36  
(−0.83 to 0.09)
0.12 3.6
Range 2.2 to 8.7 2.2 to 8.0 2.2 to 7.8
On days with no lesions
Median 4.1 3.8 −0.27  
(−0.80 to 0.26)
0.31 3.3
Range 2.2 to 7.9 2.2 to 6.9 2.2 to 7.5
On days with lesions
Median 6.1 5.7 −0.47  
(−1.19 to 0.24)
0.19 5.4
Range 2.2 to 8.7 2.2 to 8.0 2.7 to 7.8
Clinical
Days with lesions — no./total no. (%) 75/836 (9.0) 108/863 (12.5) 1.39 
(0.59 to 3.30)
0.46 30/864 (3.5)
No. of recurrences 12 18 12
Recurrence rate (annualized) 5.2 7.6 1.39 
(0.70 to 2.78)
0.36 5.1
* P values are for the comparison of each pritelivir dose group with the placebo group. A P value of less than 0.0125 was considered to indi-
cate statistical significance after Bonferroni correction for multiple comparisons. Relative risks are shown for viral shedding and clinical end 
points; changes in the log10 copy number are shown for HSV DNA.
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in participants treated with the lowest doses of 
pritelivir.
Our study design, in which the number of 
days of viral shedding was the primary outcome, 
provided an approach toward defining in vivo 
antiviral efficacy and an effective, safe dose for 
subsequent evaluation. Studies of the natural 
history of HSV-2 have shown that shedding fre-
quency, the quantity of HSV during shedding, 
and the occurrence and duration of genital lesions 
are all correlated.20 Early studies in the develop-
ment of nucleoside analogues for the treatment 
of genital herpes measured the reduction in the 
duration of symptomatic recurrences. However, 
lesions reflect mucosal damage as well as viral 
replication, and even effective antiviral agents 
have marginal benefits when started after the 
formation of lesions. Evaluations of viral shed-
ding have shown that nearly all persons with 
HSV-2 shed virus.21 We selected a patient popu-
lation with clinically symptomatic disease to 
obtain a preliminary assessment of both the ef-
fects of extended antiviral therapy on shedding 
and the potential clinical benefit of pritelivir. 
Our data indicate that pritelivir may have the 
potential to reduce clinical recurrences of HSV.
Although the HSV shedding rate was reduced 
by more than 85% at the highest doses of pri-
telivir, as compared with placebo, some break-
through shedding remained. Persistent, low-level 
shedding during nucleoside therapy has been doc-
umented previously.3 The pathogenesis of break-
through viral shedding during adequate antiviral 
therapy with nucleoside analogues is poorly un-
Relative Risk  
or Change in  
Copy Number  





or Change in  
Copy Number   




Relative Risk  
or Change in  
Copy Number  
(95% CI) P Value
0.57
(0.31 to 1.03)
0.06 16/766 (2.1) 0.13  
(0.04 to 0.38)





0.38 12/757 (1.6) 0.16 
(0.05 to 0.49)





0.03 4/9 (44.4) 0.57 
(0.16 to 2.03)





<0.001 2.4 −1.63  
(−2.57 to −0.69)
<0.001 3.6 −1.09  
(−1.68 to −0.50)
<0.001
2.2–4.8 2.2 to 6.9
−0.45
(−0.96 to 0.06)
0.08 2.4 −1.33 
(−2.45 to −0.21)
0.02 3.4 −0.57  
(−1.32 to 0.17)
0.13
2.2 to 4.8 2.2 to 6.8
−1.02
(−1.63 to −0.40)
0.001 2.9 −1.75  
(−2.09 to −1.41)
<0.001 5.2 −0.83 
(−1.11 to −0.54)
<0.001
2.4 to 3.5 4.3 to 6.9
0.41
(0.16 to 1.09) 
0.07 9/775 (1.2) 0.13 
(0.02 to 0.70) 
0.02 10/861 (1.2) 0.13  





0.75 1.4 0.28 
(0.08 to 0.95)
0.04 2.5 0.48 
(0.17 to 1.38)
0.17
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derstood; it is not related to lack of adherence to 
the treatment regimen or viral resistance.12 The 
question of whether further increases in the 
daily dose of pritelivir would completely abro-
gate viral shedding will have to be addressed in 
additional studies. As shown in Table S3 in the 
Supplementary Appendix, pritelivir had a stron-
ger effect on the reduction of viral DNA than the 
nucleoside analogues studied in earlier trials. 
Although it is appealing to compare the efficacy 
of pritelivir with that of currently licensed prod-
ucts, the frequency of viral shedding and the 
magnitude of the reduction in the quantity of 
virus shed with antiviral medication depend 
heavily on the characteristics of the participants 
enrolled; thus, a direct comparison in a clinical 
trial is warranted to properly determine com-
parative efficacy.
This study shows that pritelivir, the first in a 
new class of antiviral agents developed for the 
treatment of herpes simplex infections, is effec-
tive in suppressing viral shedding and lesion 
development in patients with genital herpes. 
Further studies will be needed to assess the 
magnitude of clinical benefit in the treatment of 


































































































































































Figure 1. Rates of Herpes Simplex Virus (HSV) Detection, Viral Load, and Recurrence of Lesions in Patients with Genital Lesions, 
 According to Study Group.
Panel A shows the percentage of days on which HSV was detected in genital samples, Panel B shows the level of HSV DNA in positive 
samples, Panel C shows the rate of subclinical shedding (i.e., detection of HSV in the absence of lesions), and Panel D shows the percent-
age of days with genital lesions. Genital samples with 150 log10 HSV DNA copies per milliliter or more were considered to be positive. 
Horizontal bars represent medians.
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of pritelivir in treating severe HSV disease and in 
reducing sexual transmission.
In May 2013, the clinical development of 
pritelivir was placed on hold by the Food and 
Drug Administration because of unexplained 
dermal and hematologic findings in a toxicology 
study of monkeys treated with daily doses rang-
ing from 75 mg per kilogram of body weight to 
1000 mg per kilogram (these doses were 70 to 
more than 900 times as high as a dose of 75 mg 
in humans). The reason for the findings in mon-
keys is currently under investigation; such find-
ings were not observed in the current trial.
Presented in part at the 19th Meeting of the International 
Society for Sexually Transmitted Diseases Research, Quebec, Can-
ada, July 10–13, 2011; and at the 36th International Herpesvirus 
Workshop, Gdansk, Poland, July 24–28, 2011.
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Table 3. Adverse Events.
Event
Placebo 
(N = 30) Pritelivir
5 mg  
Daily  
(N = 33)
25 mg  
Daily  
(N = 32)








no. of participants (%)
Any adverse event 23 (77) 27 (82) 26 (81) 27 (93) 23 (74) 103 (82)
Serious adverse events 0 0 1 (3)* 0 0 1 (1)
Adverse events leading to study 
discontinuation
0 1 (3)† 1 (3)‡ 0 1 (3)§ 3 (2)
Moderate adverse events 12 (40) 13 (39) 11 (34) 12 (41) 8 (26) 44 (35)
Severe adverse events 3 (10) 1 (3) 1 (3) 2 (7) 1 (3) 5 (4)
Common adverse events
Headache, total 12 (40) 12 (36) 14 (44) 11 (38) 14 (45) 51 (41)
Moderate 4 (13) 6 (18) 3 (9) 4 (14) 6 (19) 19 (15)
Severe 0 0 0 0 0 0 
Nausea, total 4 (13) 9 (27) 5 (16) 5 (17) 9 (29) 28 (22)
Moderate 0 4 (12) 0 0 1 (3) 5 (4)
Severe 0 0 0 0 0 0
Fatigue, total 5 (17) 4 (12) 2 (6) 5 (17) 3 (10) 14 (11)
Moderate 3 (10) 1 (3) 0 3 (10) 1 (3) 5 (4)
Severe 0 0 0 1 (3) 0 1 (<1)
Upper abdominal pain, total 3 (10) 2 (6) 4 (13) 4 (14) 2 (6) 12 (10)
Moderate 0 0 1 (3) 0 0 1 (<1)
Severe 1 (3) 0 0 0 0 1 (<1)
* Pancreatitis was reported 2 weeks after administration of the last dose in one participant, who may have had a history 
of alcohol abuse and who had a history of pancreatitis.
† Moderate headache, nausea, chest pain, and dyspnea led to discontinuation in one patient.
‡ Suspected systemic lupus erythematosus led to discontinuation in one patient.
§ Mild anxiety led to discontinuation in one patient.
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